ATR inhibitors as a synthetic lethal therapy for tumours deficient in ARID1A

Mutations in the BAF SWI/SNF complex subunits are frequent in cancers but selective therapeutic approaches are not available yet. Here, the authors demonstrate that defects ofARID1Aand other subunits sensitizes cancer cells to the DNA checkpoint kinase inhibitor ATR in a synthetic lethal manner.

Guardado en:

Detalles Bibliográficos
Autores principales:	Chris T. Williamson, Rowan Miller, Helen N. Pemberton, Samuel E. Jones, James Campbell, Asha Konde, Nicholas Badham, Rumana Rafiq, Rachel Brough, Aditi Gulati, Colm J. Ryan, Jeff Francis, Peter B. Vermulen, Andrew R. Reynolds, Philip M. Reaper, John R. Pollard, Alan Ashworth, Christopher J. Lord
Formato:	article
Lenguaje:	EN
Publicado:	Nature Portfolio 2016
Materias:	Science Q
Acceso en línea:	https://doaj.org/article/e641244f3cf24d9e87d1e6540b5b48bf
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:e641244f3cf24d9e87d1e6540b5b48bf
record_format	dspace
spelling	oai:doaj.org-article:e641244f3cf24d9e87d1e6540b5b48bf2021-12-02T14:39:14ZATR inhibitors as a synthetic lethal therapy for tumours deficient in ARID1A10.1038/ncomms138372041-1723https://doaj.org/article/e641244f3cf24d9e87d1e6540b5b48bf2016-12-01T00:00:00Zhttps://doi.org/10.1038/ncomms13837https://doaj.org/toc/2041-1723Mutations in the BAF SWI/SNF complex subunits are frequent in cancers but selective therapeutic approaches are not available yet. Here, the authors demonstrate that defects ofARID1Aand other subunits sensitizes cancer cells to the DNA checkpoint kinase inhibitor ATR in a synthetic lethal manner.Chris T. WilliamsonRowan MillerHelen N. PembertonSamuel E. JonesJames CampbellAsha KondeNicholas BadhamRumana RafiqRachel BroughAditi GulatiColm J. RyanJeff FrancisPeter B. VermulenAndrew R. ReynoldsPhilip M. ReaperJohn R. PollardAlan AshworthChristopher J. LordNature PortfolioarticleScienceQENNature Communications, Vol 7, Iss 1, Pp 1-13 (2016)
institution	DOAJ
collection	DOAJ
language	EN
topic	Science Q
spellingShingle	Science Q Chris T. Williamson Rowan Miller Helen N. Pemberton Samuel E. Jones James Campbell Asha Konde Nicholas Badham Rumana Rafiq Rachel Brough Aditi Gulati Colm J. Ryan Jeff Francis Peter B. Vermulen Andrew R. Reynolds Philip M. Reaper John R. Pollard Alan Ashworth Christopher J. Lord ATR inhibitors as a synthetic lethal therapy for tumours deficient in ARID1A
description	Mutations in the BAF SWI/SNF complex subunits are frequent in cancers but selective therapeutic approaches are not available yet. Here, the authors demonstrate that defects ofARID1Aand other subunits sensitizes cancer cells to the DNA checkpoint kinase inhibitor ATR in a synthetic lethal manner.
format	article
author	Chris T. Williamson Rowan Miller Helen N. Pemberton Samuel E. Jones James Campbell Asha Konde Nicholas Badham Rumana Rafiq Rachel Brough Aditi Gulati Colm J. Ryan Jeff Francis Peter B. Vermulen Andrew R. Reynolds Philip M. Reaper John R. Pollard Alan Ashworth Christopher J. Lord
author_facet	Chris T. Williamson Rowan Miller Helen N. Pemberton Samuel E. Jones James Campbell Asha Konde Nicholas Badham Rumana Rafiq Rachel Brough Aditi Gulati Colm J. Ryan Jeff Francis Peter B. Vermulen Andrew R. Reynolds Philip M. Reaper John R. Pollard Alan Ashworth Christopher J. Lord
author_sort	Chris T. Williamson
title	ATR inhibitors as a synthetic lethal therapy for tumours deficient in ARID1A
title_short	ATR inhibitors as a synthetic lethal therapy for tumours deficient in ARID1A
title_full	ATR inhibitors as a synthetic lethal therapy for tumours deficient in ARID1A
title_fullStr	ATR inhibitors as a synthetic lethal therapy for tumours deficient in ARID1A
title_full_unstemmed	ATR inhibitors as a synthetic lethal therapy for tumours deficient in ARID1A
title_sort	atr inhibitors as a synthetic lethal therapy for tumours deficient in arid1a
publisher	Nature Portfolio
publishDate	2016
url	https://doaj.org/article/e641244f3cf24d9e87d1e6540b5b48bf
work_keys_str_mv	AT christwilliamson atrinhibitorsasasyntheticlethaltherapyfortumoursdeficientinarid1a AT rowanmiller atrinhibitorsasasyntheticlethaltherapyfortumoursdeficientinarid1a AT helennpemberton atrinhibitorsasasyntheticlethaltherapyfortumoursdeficientinarid1a AT samuelejones atrinhibitorsasasyntheticlethaltherapyfortumoursdeficientinarid1a AT jamescampbell atrinhibitorsasasyntheticlethaltherapyfortumoursdeficientinarid1a AT ashakonde atrinhibitorsasasyntheticlethaltherapyfortumoursdeficientinarid1a AT nicholasbadham atrinhibitorsasasyntheticlethaltherapyfortumoursdeficientinarid1a AT rumanarafiq atrinhibitorsasasyntheticlethaltherapyfortumoursdeficientinarid1a AT rachelbrough atrinhibitorsasasyntheticlethaltherapyfortumoursdeficientinarid1a AT aditigulati atrinhibitorsasasyntheticlethaltherapyfortumoursdeficientinarid1a AT colmjryan atrinhibitorsasasyntheticlethaltherapyfortumoursdeficientinarid1a AT jefffrancis atrinhibitorsasasyntheticlethaltherapyfortumoursdeficientinarid1a AT peterbvermulen atrinhibitorsasasyntheticlethaltherapyfortumoursdeficientinarid1a AT andrewrreynolds atrinhibitorsasasyntheticlethaltherapyfortumoursdeficientinarid1a AT philipmreaper atrinhibitorsasasyntheticlethaltherapyfortumoursdeficientinarid1a AT johnrpollard atrinhibitorsasasyntheticlethaltherapyfortumoursdeficientinarid1a AT alanashworth atrinhibitorsasasyntheticlethaltherapyfortumoursdeficientinarid1a AT christopherjlord atrinhibitorsasasyntheticlethaltherapyfortumoursdeficientinarid1a
_version_	1718390745103073280

ATR inhibitors as a synthetic lethal therapy for tumours deficient in ARID1A

Ejemplares similares